#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	13758	16S	1529	1529	99.93	16S.l6.c30.ctg.1	2108	649.8	0	.	n	.	0	C1450T	SNP	1450	1450	C	1767	1767	T	716	T	660	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	13758	16S	1529	1529	99.93	16S.l6.c30.ctg.1	2108	649.8	1	SNP	n	C1184T	0	.	.	1184	1184	C	1501	1501	C	828	C,A	762,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25764	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3539	725.4	0	.	n	.	0	G1337A	SNP	1337	1337	G	1643	1643	A	881	A	814	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25764	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3539	725.4	0	.	n	.	0	T1971C	SNP	1971	1971	T	2277	2277	C	780	C,T,G	717,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25764	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3539	725.4	1	SNP	n	A2045G	0	.	.	2045	2045	A	2351	2351	A	839	A	786	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	25764	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3539	725.4	1	SNP	n	C2597T	0	.	.	2597	2597	C	2903	2903	C	876	C	820	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	2032	folP	855	855	100.0	folP.l15.c17.ctg.1	1434	140.9	1	SNP	p	R229S	1	.	.	685	687	AGC	948	950	AGC	222;222;221	A;G;C	210;210;208	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5384	gyrA	2751	2751	99.96	gyrA.l15.c30.ctg.1	3300	162.4	1	SNP	p	S91F	1	.	.	271	273	TTC	507	509	TTC	188;187;189	T;T;C	180;179;181	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5384	gyrA	2751	2751	99.96	gyrA.l15.c30.ctg.1	3300	162.4	1	SNP	p	D95G	1	.	.	283	285	GGC	519	521	GGC	181;183;182	G;G;C,G	171;172;167,1	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5384	gyrA	2751	2751	99.96	gyrA.l15.c30.ctg.1	3300	162.4	1	SNP	p	G95N	0	.	.	283	285	GGC	519	521	GGC	181;183;182	G;G;C,G	171;172;167,1	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	27	1668	mtrR	633	633	100.0	mtrR.l15.c30.ctg.1	1279	129.8	1	SNP	p	G45D	0	.	.	133	135	GGC	447	449	GGC	228;224;225	G;G;C	209;203;201	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	782	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c17.ctg.1	1010	77.2	0	.	n	.	0	A197.	DEL	197	197	A	609	609	A	186	A	182	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4964	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2973	166.2	0	.	p	.	0	I384V	NONSYN	1150	1152	ATC	1482	1484	GTC	204;201;201	G,A;T;C	187,1;184;186	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4964	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2973	166.2	1	SNP	p	D86N	0	.	.	256	258	GAC	588	590	GAC	235;239;239	G;A;C	212;216;220	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4964	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2973	166.2	1	SNP	p	R87I	0	.	.	259	261	CGT	591	593	CGT	244;246;245	C;G;T	221;225;221	parC.WHO_V_00204c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4964	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2973	166.2	1	SNP	p	S87R	1	.	.	259	261	CGT	591	593	CGT	244;246;245	C;G;T	221;225;221	parC.WHO_V_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4964	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2973	166.2	1	SNP	p	R87W	0	.	.	259	261	CGT	591	593	CGT	244;246;245	C;G;T	221;225;221	parC.WHO_V_00204c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4964	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2973	166.2	1	SNP	p	S88P	0	.	.	262	264	TCC	594	596	TCC	246;248;245	T;C;C	222;225;227	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4362	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2648	164.1	0	.	p	.	0	R340C	NONSYN	1018	1020	CGC	1393	1395	TGC	206;209;210	T;G;C,T	196;197;201,1	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4362	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2648	164.1	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1603	1605	GGC	214;215;213	G;G;C	202;200;196	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.12.001	penA.12.001	1	1	27	3876	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2448	157.7	1	SNP	p	A311V	0	.	.	931	933	GCA	1335	1337	GCA	222;222;226	G;C;A	198;199;206	penA.12.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3876	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2448	157.7	1	SNP	p	I312M	0	.	.	934	936	ATC	1338	1340	ATC	226;225;225	A;T;C	203;204;204	penA.12.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3876	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2448	157.7	1	SNP	p	V316T	0	.	.	946	948	GTG	1350	1352	GTG	217;216;215	G;T,A;G	199;193,1;198	penA.12.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3876	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2448	157.7	1	SNP	p	V316P	0	.	.	946	948	GTG	1350	1352	GTG	217;216;215	G;T,A;G	199;193,1;198	penA.12.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3876	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2448	157.7	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1854	1856	ACC	201;201;203	A;C;C	181;184;183	penA.12.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3876	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2448	157.7	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1908	1910	GCG	203;206;204	G,A;C,G;G	183,1;169,1;174	penA.12.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3876	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2448	157.7	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1908	1910	GCG	203;206;204	G,A;C,G;G	183,1;169,1;174	penA.12.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3876	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2448	157.7	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2031	2033	GGC	193;191;190	G;G;C	174;172;174	penA.12.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3876	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2448	157.7	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2040	2042	GGC	193;192;195	G;G;C	171;171;171	penA.12.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3876	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2448	157.7	1	SNP	p	P552S	1	.	.	1654	1656	TCG	2058	2060	TCG	176;180;176	T,G,C;C;G	121,3,1;149;149	penA.12.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5702	ponA	2397	2397	100.0	ponA.l15.c30.ctg.1	3104	183.1	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1654	1656	CCG	222;219;217	C;C;G	194;198;191	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2192	porA	1146	1146	99.56	porA.l15.c4.ctg.1	1704	128.1	0	.	p	.	0	M83fs	FSHIFT	247	247	A	482	482	C	169	C	146	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2522	porB1b	1041	1041	97.42	porB1b.l15.c17.ctg.1	1631	153.5	0	.	p	.	0	T87A	NONSYN	259	261	ACT	630	632	GCT	203;205;207	G;C;T	186;189;189	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2522	porB1b	1041	1041	97.42	porB1b.l15.c17.ctg.1	1631	153.5	0	.	p	.	0	T89S	NONSYN	265	267	ACC	636	638	AGC	200;198;200	A;G;C	190;187;186	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2522	porB1b	1041	1041	97.42	porB1b.l15.c17.ctg.1	1631	153.5	0	.	p	.	0	K120D	NONSYN	358	360	AAG	729	731	GAC	192;191;189	G,A;A,G;C,G,T	183,1;180,1;179,1,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2522	porB1b	1041	1041	97.42	porB1b.l15.c17.ctg.1	1631	153.5	0	.	p	.	0	N124G	NONSYN	370	372	AAT	741	743	GGT	202;203;203	G,A;G,A;T	192,2;193,2;190	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2522	porB1b	1041	1041	97.42	porB1b.l15.c17.ctg.1	1631	153.5	0	.	p	.	0	E137K	NONSYN	409	411	GAA	780	782	AAA	199;201;202	A,G;A;A	180,2;185;184	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2522	porB1b	1041	1041	97.42	porB1b.l15.c17.ctg.1	1631	153.5	0	.	p	.	0	K143Q	NONSYN	427	429	AAA	798	800	CAA	213;212;210	C,A;A,G;A	195,2;195,1;195	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2522	porB1b	1041	1041	97.42	porB1b.l15.c17.ctg.1	1631	153.5	0	.	p	.	0	V151A	NONSYN	451	453	GTA	822	824	GCA	211;210;214	G;C,T;A	198;196,1;196	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2522	porB1b	1041	1041	97.42	porB1b.l15.c17.ctg.1	1631	153.5	0	.	p	.	0	G253Q	NONSYN	757	759	GGA	1128	1130	CAA	190;189;187	C;A;A	181;181;180	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2522	porB1b	1041	1041	97.42	porB1b.l15.c17.ctg.1	1631	153.5	0	.	p	.	0	.	INDELS	760	761	AC	1132	1135	ATCA	182;183;182;183	A;T;C;A	176;177;177;177	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2522	porB1b	1041	1041	97.42	porB1b.l15.c17.ctg.1	1631	153.5	0	.	p	.	0	.	INDELS	763	764	TG	1139	1141	AGT	182;185;183	A;G;T	175;179;175	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2522	porB1b	1041	1041	97.42	porB1b.l15.c17.ctg.1	1631	153.5	0	.	p	.	0	A257D	NONSYN	769	771	GCT	1146	1148	GAT	178;178;178	G;A,C;T	166;168,1;170	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2522	porB1b	1041	1041	97.42	porB1b.l15.c17.ctg.1	1631	153.5	0	.	p	.	0	D293S	NONSYN	877	879	GAT	1254	1256	AGT	197;194;194	A;G;T	180;177;173	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2522	porB1b	1041	1041	97.42	porB1b.l15.c17.ctg.1	1631	153.5	0	.	p	.	0	N295D	NONSYN	883	885	AAC	1260	1262	GAC	190;191;189	G;A;C	169;173;172	.	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	9992	rpoB	4179	4179	99.98	rpoB.l15.c17.ctg.1	4818	206.8	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2000	2002	CAT	191;190;190	C;A;T	181;180;180	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1056	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1161	90.7	1	SNP	p	V57M	1	.	.	169	171	ATG	582	584	ATG	254;253;254	A;T;G	235;233;235	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
